Abstract Body

Background: Combination antiretroviral therapy (cART) initiated within three months of birth is not only effective in controlling HIV-1 replication and preserving immune function but also markedly reduces HIV-1 related mortality. Early diagnosis of HIV-1 infected infants and initiation of cART is thus recommended globally. The development of highly sensitive assays has facilitated the characterization of HIV-1 persistence in*early-treated infants. Durable suppression of HIV-1 replication is associated with lack of detectable plasma viremia (LOD 2 copies/ml) limited T cell activation and absent HIV-1 specific immune responses. Under these conditions proviral and replication-competent reservoirs decline steeply over the first year of therapy; continued reductions result in extremely low levels of proviral DNA and lack of recoverable replication-competent HIV-1 after a decade or more of suppressive therapy. The decay in PBMC HIV-1 proviral DNA and replication-competent HIV-1 in the absence of detectable HIV-specific immune responses suggest that early cART limits seeding of long-lived cellular reservoirs. This may be particularly true in infants where primary HIV-1 infection occurs in the context of a developing immune system. Additional support for this hypothesis is provided by a previously reported case of a very early-treated HIV-1 infected child who controlled HIV-1 viremia off therapy after receiving cART between 30 hours and 18 months of age as well as preliminary data from studies of infected CD4+ T cell subsets. Conclusions: Early and very early cART restrict the numbers of long-lived CD4+ T cells that harbor HIV-1 DNA and replication-competent virus which serve as the barrier to cure. Continued refinement of assays to measure and characterize viral reservoirs in early-treated children should further improve our understanding of HIV persistence define markers predictive of successful control of HIV-1 replication off cART and lead to the conduct of additional trials aimed at sparing children a lifetime of therapy.